Cyclooxygenation of the arachidonoyl side chain of 1-arachidonoylglycerol and related compounds block their ability to prevent anandamide and 2-oleoylglycerol metabolism by rat brain in vitro.
In the present study, the abilities of cyclooxygenated derivatives of 1-arachidonoylglycerol and related compounds to prevent the metabolism of [3H]2-oleoylglycerol and [3H]anandamide by cytosolic and membrane fractions, respectively, have been investigated. For each compound, nine concentrations (range 0.2-100 microM) were tested. 1-Arachidonoylglycerol inhibited the hydrolysis of [3H]2-oleoylglycerol with a pI50 value of 5.17+/-0.04 (maximum attainable inhibition 88%). In contrast, the 1-glyceryl esters of prostaglandin D2, E2 and F2alpha were very weak inhibitors of this hydrolysis. Similarly, prostaglandin D2, prostaglandin D2 ethanolamide and prostaglandin D2 serinol amide produced <20% inhibition of [3H]2-oleoylglycerol metabolism at any concentration tested, in contrast to previous data with arachidonic acid, anandamide and arachidonoyl serinol which are all able to inhibit metabolism of this substrate under the assay conditions used here. A similar pattern was seen for all the compounds with respect to the inhibition of [3H]anandamide hydrolysis by the membrane fractions. Thus, cyclooxygenation of the arachidonoyl side chain greatly reduces the ability of 1-arachidonoylglycerol and related compounds to inhibit the hydrolysis of [3H]2-oleoylglycerol and [3H]anandamide.
Fowler
Christopher J
CJ
Department of Pharmacology and Clinical Neuroscience, Umeå University, SE-90187 Umeå, Sweden. cf@pharm.umu.se
Tiger
Gunnar
G
D000581:Amidohydrolases / Q000378:metabolism; D000818:Animals; D001095:Arachidonic Acids / Q000037:antagonists & inhibitors*; D001921:Brain / Q000166:cytology / Q000378:metabolism*; D002458:Cell Fractionation; D002462:Cell Membrane / Q000737:chemistry / Q000187:drug effects; D003600:Cytosol / Q000737:chemistry / Q000187:drug effects; D004075:Diglycerides / Q000378:metabolism; D015237:Dinoprost / Q000037:antagonists & inhibitors; D015232:Dinoprostone / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D004305:Dose-Response Relationship, Drug; D063388:Endocannabinoids; D005989:Glycerides / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D006868:Hydrolysis / Q000187:drug effects; D020128:Inhibitory Concentration 50; D008994:Monoacylglycerol Lipases / Q000378:metabolism; D053284:Polyunsaturated Alkamides; D015230:Prostaglandin D2 / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D051381:Rats; D017207:Rats, Sprague-Dawley; D014316:Tritium; D000099252:Fatty Acid Amide Hydrolases
D000581:Amidohydrolases; D001095:Arachidonic Acids; D004075:Diglycerides; D015237:Dinoprost; D015232:Dinoprostone; D063388:Endocannabinoids; D005989:Glycerides; D008994:Monoacylglycerol Lipases; D053284:Polyunsaturated Alkamides; D015230:Prostaglandin D2; D014316:Tritium; D000099252:Fatty Acid Amide Hydrolases; C477658:1-arachidonylglycerol; C493493:prostaglandin D2 ethanolamide; C078814:anandamide; C013965:diolein